123 related articles for article (PubMed ID: 35108788)
1. The Effect of FDG-PET/CT on Clinical Prognostic Staging of Breast Cancer Patients being Planned Neoadjuvant Treatment.
Simsek ET; Coban E; Atag E; Gungor S; Aker F; Sari M
J Coll Physicians Surg Pak; 2022 Feb; 32(2):181-185. PubMed ID: 35108788
[TBL] [Abstract][Full Text] [Related]
2. Clinical Utility of 18F-FDG PET/CT in Staging Localized Breast Cancer Before Initiating Preoperative Systemic Therapy.
Ko H; Baghdadi Y; Love C; Sparano JA
J Natl Compr Canc Netw; 2020 Sep; 18(9):1240-1246. PubMed ID: 32886897
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.
Groheux D; Hindié E; Delord M; Giacchetti S; Hamy AS; de Bazelaire C; de Roquancourt A; Vercellino L; Toubert ME; Merlet P; Espié M
J Natl Cancer Inst; 2012 Dec; 104(24):1879-87. PubMed ID: 23243198
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years.
Riedl CC; Slobod E; Jochelson M; Morrow M; Goldman DA; Gonen M; Weber WA; Ulaner GA
J Nucl Med; 2014 Oct; 55(10):1578-83. PubMed ID: 25214641
[TBL] [Abstract][Full Text] [Related]
5. The value of 18F-FDG PET/CT imaging in breast cancer staging.
Yararbas U; Avci NC; Yeniay L; Argon AM
Bosn J Basic Med Sci; 2018 Feb; 18(1):72-79. PubMed ID: 28763628
[TBL] [Abstract][Full Text] [Related]
6. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
7.
Ulaner GA; Castillo R; Wills J; Gönen M; Goldman DA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1420-1427. PubMed ID: 28456837
[TBL] [Abstract][Full Text] [Related]
8. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
[TBL] [Abstract][Full Text] [Related]
9. The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study.
Groheux D; Giacchetti S; Espié M; Vercellino L; Hamy AS; Delord M; Berenger N; Toubert ME; Misset JL; Hindié E
J Nucl Med; 2011 Oct; 52(10):1526-34. PubMed ID: 21880576
[TBL] [Abstract][Full Text] [Related]
10. Subtype-Guided
Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
[TBL] [Abstract][Full Text] [Related]
11. Role of
Reddy Akepati NK; Abubakar ZA; Bikkina P
Indian J Nucl Med; 2018; 33(3):190-193. PubMed ID: 29962713
[TBL] [Abstract][Full Text] [Related]
12. Performance of FDG PET/CT in the clinical management of breast cancer.
Groheux D; Espié M; Giacchetti S; Hindié E
Radiology; 2013 Feb; 266(2):388-405. PubMed ID: 23220901
[TBL] [Abstract][Full Text] [Related]
13. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
14. Elevated tumor-to-liver uptake ratio (TLR) from
Huang J; Huang L; Zhou J; Duan Y; Zhang Z; Wang X; Huang P; Tan S; Hu P; Wang J; Huang M
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1958-1968. PubMed ID: 28812134
[TBL] [Abstract][Full Text] [Related]
15. ¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.
Cochet A; Dygai-Cochet I; Riedinger JM; Humbert O; Berriolo-Riedinger A; Toubeau M; Guiu S; Coutant C; Coudert B; Fumoleau P; Brunotte F
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):428-37. PubMed ID: 24196916
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer.
Risum S; Loft A; Engelholm SA; Høgdall E; Berthelsen AK; Nedergaard L; Lundvall L; Høgdall C
Int J Gynecol Cancer; 2012 Sep; 22(7):1163-9. PubMed ID: 22810969
[TBL] [Abstract][Full Text] [Related]
17.
Ulaner GA; Juarez J; Riedl CC; Goldman DA
J Nucl Med; 2019 Apr; 60(4):472-477. PubMed ID: 30237211
[No Abstract] [Full Text] [Related]
18. PET/CT with
Teixeira SC; Koolen BB; Elkhuizen PH; Vrancken Peeters MT; Stokkel MP; Rodenhuis S; van der Noort V; Rutgers EJ; Valdés Olmos RA
Eur J Surg Oncol; 2017 Apr; 43(4):625-635. PubMed ID: 27847287
[TBL] [Abstract][Full Text] [Related]
19. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
[TBL] [Abstract][Full Text] [Related]
20. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]